In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

How do we get the patients to stop smoking in cardiac rehabilitation programs?

Session Poster Session III - Saturday 08:30 - 12:30

Speaker Veronica Angela Rial Baston

Congress : EuroPrevent 2017

  • Topic : preventive cardiology
  • Sub-topic : Tobacco
  • Session type : Poster Session
  • FP Number : 771

Authors : V Rial Baston (Madrid,ES), R Dalmau Gonzalez-Gallarza (Madrid,ES), FJ Irazusta Cordoba (Madrid,ES), P Meras Colunga (Madrid,ES), O Gonzalez Fernandez (Madrid,ES), AM Iniesta Manjavacas (Madrid,ES), R Mori Junco (Madrid,ES), C Alvarez Ortega (Madrid,ES), A Castro Conde (Madrid,ES), JL Lopez Sendon Hentschel (Madrid,ES)

Authors:
V Rial Baston1 , R Dalmau Gonzalez-Gallarza1 , FJ Irazusta Cordoba1 , p Meras Colunga1 , O Gonzalez Fernandez1 , AM Iniesta Manjavacas1 , R Mori Junco1 , C Alvarez Ortega1 , A Castro Conde1 , JL Lopez Sendon Hentschel1 , 1University Hospital La Paz, Cardiology - Madrid - Spain ,

Citation:
European Journal of Preventive Cardiology ( April 2017 ) 24 ( Supplement 1 ), 171

Background: Cardiac rehabilitation programs (CRP) are class I indication in clinical guidelines as they have proved to be a cost-effective secondary prevention intervention. One of their main goals is to achieve smoking cessation since it has shown to reduce the risk of mortality by 33% in patients with coronary artery disease. Objectives and
Methods: Data were collected retrospectively of 573 smokers referred to a CRP between May 2006 and January 2015 after having suffered an acute coronary syndrome. Our objective is to determine the critical success factors of the program measuring by co-oximetry the abstinence rate at 3 months and evaluating its impact on other factors.
Results: 84.5% were male, with a mean age of 53,37±9,74 years. The average of pack years of cigarette smoking was 43.53. Every patient (P.) attended briefings, being also necessary pharmacological treatment prescription in 21.2% of the patients (varenicline (V) was used in 11.3%; bupropion (Bp) in 1%, nicotine replacement therapy (NRT) in 4.3%, NRT and one drug in 3.3% and NRT and two drugs in 1.2%). Pharmacological treatment use was more common among women, young patients and those with higher pack-year consumption (p<0.05). At the third month, 437 P. (80%) had quitted smoking (88.9% of patients who were not treated with drugs and 48.5% of patients who needed pharmacological treatment, p<0.05). In this subgroup, 65% of patients treated with V or Bp left tobacco consumption in comparison to 28.6% of P. treated with NRT and 22.4% of P. treated with both therapies. Sex, age, obesity and other risk factors did not influence abstinence rates whereas higher pack-year consumption was significantly associated with less success (41,31 vs 52,90, p=0,03). The persistence of smoking implied less functional capacity (10,06 METS vs 10,76, p=0,02) and higher CRP dropout rates (31,4% vs 5,4%; p<0,05); however it did not affect weight, blood pressure values, glycosilated hemoglobin or lipid levels at discharge.
Conclusion: CRP achieve high rates of smoking cessation; in our experience the most effective interventions are motivational support and varenicline (if pharmacological treatment is necessary). A higher pack year consumption reduced the likelihood of abstinence at 3 months.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are